Government Owned Invention Available for License: Chimeric Antigen Receptors Targeting the Gamma Delta (γδ) T-Cell Receptor

Document Headings Document headings vary by document type but may contain the following: the agency or agencies that issued and signed a document the number of the CFR title and the number of each part the document amends, proposes to amend, or is directly related to the agency docket number / agency internal file number the RIN which identifies each regulatory action listed in the Unified Agenda of Federal Regulatory and Deregulatory Actions See the Document Drafting Handbook for more details. Department of Health and Human Services National Institutes of Health AGENCY: National Institutes of Health, HHS. ACTION: Notice. SUMMARY: The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for a set of Chimeric Antigen Receptors (CARs) that target the γδ T-Cell Receptor. FOR FURTHER INFORMATION CONTACT: Inquiries related to this license opportunity should be directed to: Andrew Burke, Ph.D. Senior Technology Transfer Manager at Email: burkear@mail.nih.gov or Phone: 240-276-5484. SUPPLEMENTARY INFORMATION: T cells express two main types of receptors based on the proteins that make up the T-cell receptor (TCR) heterodimers: αβ (alpha beta) and γδ (gamma delta). T cells expressing the γδ TCR are detected at lower frequencies compared with T cells expressing the αβ TCR. γδ T cells make up 0.3-10% of peripheral blood T cells. The γδ TCR is expressed on the cell surface of several aggressive cancers, including—but not limited to—hepatosplenic T-cell lymphoma, primary cutaneous γδ T-cell lymphoma and T-cell acute lymphoblastic leukemia (T-ALL). These cancers carry poor prognosis as they are often resistant to chemotherapy. In addition, to their roles in cancer development, γδ T cells may also play role in autoimmune diseases, including psoriasis, rheumatoid arthritis, multiple sclerosis and myositis. There is evidence that &g…